In the CALERIE-2 trial, both groups showed improvement in fasting insulin levels and the related HOMA-IR but neither group showed a change in cognitive performance [26,34,35], suggesting that obesity and its metabolic effects at baseline may be necessary for an effect on cognitive function to occur. The gene discussed is INS; the disease is obesity disorder.